Our findings suggest that exposure to EMsOI increases the levels of the pro-inflammatory factor Interleukin-9, potentially worsening EMs, while reducing the levels of pro-inflammatory factors IL-13 and IL-31. Here, IL13 is linked to eosinophilia-myalgia syndrome.